|Delayed - 01/19 04:00:00 pm|
Dynavax Technologies : MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID-19 VACCINE CANDIDATE
|11/11/2020 | 08:40am|
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19.
The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago's COVID-19 adjuvanted vaccine candidate.
'These are very promising results. After two doses, the adjuvanted vaccine candidate induced robust neutralizing antibody and cellular immune responses which is encouraging and support further clinical evaluation,' said
There were no severe adverse events reported and reactogenicity events were generally mild to moderate and short in duration.
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy subjects, male and female aged 18-55, and evaluated dosages of 3.75, 7.5 or 15 micrograms of the recombinant Coronavirus Virus-Like Particle (CoVLP) vaccine candidate alone or with an adjuvant in a prime-boost regimen. Medicago tested its vaccine candidate with each of the two adjuvants - GSK's proprietary pandemic adjuvant technology and
'The positive results of our Phase 1 clinical trial are a step forward in the fight against the COVID-19 pandemic and we are confidently moving forward to our Phase 2/3 trial. We're pleased that Medicago's innovative manufacturing technology is helping to diversify the classes of COVID-19 vaccines candidates in development. In addition to supplying up to 76 million doses to the
The data from the interim analysis have been published on an online preprint server at medRxiv.org.
About Phase 1 results summary
Side effects were mainly mild to moderate and of short duration with no serious adverse events. Safety follow-up continues.
Phase 1 immunogenicity results demonstrate that adjuvants have the potential to improve humoral and cellular immune responses compared to the non-adjuvanted formulations.
All subjects in the group with GSK's pandemic adjuvant developed anti-spike IgG antibodies after a single dose of vaccine - either 3.75, 7.5 and 15 -microg.
100 per cent of participants who received an adjuvanted formulation developed neutralizing antibody responses after Dose 2 for all dose groups.
Anti-spike IgG and viral neutralization responses compared favorably to responses from COVID-19 positive patients outside of the study.
GSK's pandemic adjuvant was dose-sparing, with the lower 3.75 -microg dose of CoVLP performing comparably with the 7.5 or the 15 -microg doses.
Cellular Th1 immune responses of participants who received 3.75 or 7.5 -microg doses were significantly higher in the adjuvanted formulations
CoVLP finished product is a liquid formulation that can be stored at 2-degreeC to 8-degreeC, easing cold chain management with existing vaccine infrastructure.
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the
(C) 2020 Electronic News Publishing, source